168 related articles for article (PubMed ID: 21819166)
21. A cost-effectiveness analysis of axillary node dissection in postmenopausal women with estrogen receptor-positive breast cancer and clinically negative axillary nodes.
Orr RK; Col NF; Kuntz KM
Surgery; 1999 Sep; 126(3):568-76. PubMed ID: 10486611
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
Delea TE; El-Ouagari K; Karnon J; Sofrygin O
Breast Cancer Res Treat; 2008 Apr; 108(3):375-87. PubMed ID: 17653859
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness analysis of 5 years of postoperative adjuvant tamoxifen therapy for Korean women with breast cancer: retrospective cohort study of the Korean breast cancer society database.
Yang JJ; Park SK; Cho LY; Han W; Park B; Kim H; Lee KS; Hahn SK; Cho SI; Ahn SH; Noh DY;
Clin Ther; 2010 Jun; 32(6):1122-38. PubMed ID: 20637966
[TBL] [Abstract][Full Text] [Related]
24. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of adjuvant radiotherapy in intermediate risk endometrial cancer.
Rankins NC; Secord AA; Jewell E; Havrilesky LJ; Soper JT; Myers E
Gynecol Oncol; 2007 Aug; 106(2):388-93. PubMed ID: 17509672
[TBL] [Abstract][Full Text] [Related]
26. Comparative effectiveness and cost-effectiveness of the implantable miniature telescope.
Brown GC; Brown MM; Lieske HB; Lieske PA; Brown KS; Lane SS
Ophthalmology; 2011 Sep; 118(9):1834-43. PubMed ID: 21723614
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model.
Hillner BE; Smith TJ
N Engl J Med; 1991 Jan; 324(3):160-8. PubMed ID: 1898533
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States.
Lyman GH; Lalla A; Barron RL; Dubois RW
Clin Ther; 2009 May; 31(5):1092-104. PubMed ID: 19539110
[TBL] [Abstract][Full Text] [Related]
29. Is adjuvant therapy for older patients with node (-) early breast cancer cost-effective?
Naeim A; Keeler EB
Crit Rev Oncol Hematol; 2005 Jan; 53(1):81-9. PubMed ID: 15607936
[TBL] [Abstract][Full Text] [Related]
30. A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score® assay in oestrogen receptor positive node negative breast cancer.
Davidson JA; Cromwell I; Ellard SL; Lohrisch C; Gelmon KA; Shenkier T; Villa D; Lim H; Sun S; Taylor S; Taylor M; Czerkawski B; Hayes M; Ionescu DN; Yoshizawa C; Chao C; Peacock S; Chia SK
Eur J Cancer; 2013 Jul; 49(11):2469-75. PubMed ID: 23611660
[TBL] [Abstract][Full Text] [Related]
31. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Marchetti M; Caruggi M; Colombo G
Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of radiation therapy following conservative surgery for ductal carcinoma in situ of the breast.
Suh WW; Hillner BE; Pierce LJ; Hayman JA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1054-61. PubMed ID: 15752884
[TBL] [Abstract][Full Text] [Related]
33. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization.
Klang SH; Hammerman A; Liebermann N; Efrat N; Doberne J; Hornberger J
Value Health; 2010; 13(4):381-7. PubMed ID: 20412544
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness analysis of intraoperative radiation therapy for early-stage breast cancer.
Alvarado MD; Mohan AJ; Esserman LJ; Park CC; Harrison BL; Howe RJ; Thorsen C; Ozanne EM
Ann Surg Oncol; 2013 Sep; 20(9):2873-80. PubMed ID: 23812769
[TBL] [Abstract][Full Text] [Related]
35. The Lifetime Economic Burden of Inaccurate HER2 Testing: Estimating the Costs of False-Positive and False-Negative HER2 Test Results in US Patients with Early-Stage Breast Cancer.
Garrison LP; Babigumira JB; Masaquel A; Wang BC; Lalla D; Brammer M
Value Health; 2015 Jun; 18(4):541-6. PubMed ID: 26091608
[TBL] [Abstract][Full Text] [Related]
36. Genomic profile of breast cancer: cost-effectiveness analysis from the Spanish National Healthcare System perspective.
Seguí MÁ; Crespo C; Cortés J; Lluch A; Brosa M; Becerra V; Chiavenna SM; Gracia A
Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):889-99. PubMed ID: 25213317
[TBL] [Abstract][Full Text] [Related]
37. Cost-Effectiveness of Chemotherapy for Breast Cancer and Age Effect in Older Women.
Lairson DR; Parikh RC; Cormier JN; Chan W; Du XL
Value Health; 2015 Dec; 18(8):1070-8. PubMed ID: 26686793
[TBL] [Abstract][Full Text] [Related]
38. Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009.
Dinan MA; Mi X; Reed SD; Hirsch BR; Lyman GH; Curtis LH
JAMA Oncol; 2015 May; 1(2):158-66. PubMed ID: 26181015
[TBL] [Abstract][Full Text] [Related]
39. Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer.
Stenehjem DD; Bellows BK; Yager KM; Jones J; Kaldate R; Siebert U; Brixner DI
Oncologist; 2016 Feb; 21(2):196-204. PubMed ID: 26614710
[TBL] [Abstract][Full Text] [Related]
40. The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer.
Garrison LP; Veenstra DL
Value Health; 2009; 12(8):1118-23. PubMed ID: 19624617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
